FaB

Fractures and Bisphosphonates: A double-blind, randomised controlled trial on the effect of alendronic acid on healing and clinical outcomes of wrist fractures.

This study aims to find out if alendronic acid, a drug widely used in post-menopausal women with osteoporosis to prevent bone fractures, has any effect on the healing of wrist fractures.
 
FaB logo
Chief Investigator: Professor Stuart Ralston
Number and location of participating sites (by region/ country): 16 UK sites
EudraCT number: 2011-000988-28
 
Funder: Arthritis Research UK
Start and End date:
of grant award:  Feb 2011- 31 Nov 2016
 
Current Status: Now published - https://doi.org/10.1002/jbmr.3679               

View the protocol document. 

 
Trial Unblinding Information: Please refer to the study protocol.
 
UK GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with UK GDPR, please read this document.
ECTU FaB GDPR privacy statement (767.94 KB / 0_11JUL2018)
 
Contact details: Sponsor(s) University of Edinburgh / NHS Lothian 
Further details, please contact
Prof Stuart Ralston, Western General Hospital, Molecular Medicine Centre, Western General Hospital, Edinburgh, EH4 2XU. 
Mr Chris Tuck, Edinburgh Clinical Trials Unit, University of Edinburgh, Nine Edinburgh Bioquarter, 9 Little France Road, EDINBURGH, EH16 4UX. 
 
ECTU Involvement: Trial Management, statistics and data management, research nurses.
(UKCRC)

This article was published on